<DOC>
	<DOCNO>NCT00005630</DOCNO>
	<brief_summary>RATIONALE : Vaccines may make body build immune response kill tumor cell . Colony-stimulating factor sargramostim may increase number immune cell find bone marrow peripheral blood . PURPOSE : Phase I trial study effectiveness vaccine therapy sargramostim treat patient non-small cell lung cancer .</brief_summary>
	<brief_title>Vaccine Therapy Sargramostim Treating Patients With Non-small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine whether specific T-cell response induce patient stage IB-IV non-small cell lung cancer treat mutant K-ras peptide vaccine ( limited specific K-ras peptide mutation tumor ) sargramostim ( GM-CSF ) . - Determine whether skin test reactivity HLA type correlate induction anti-K-ras immune response patient treat regimen . - Determine toxicity regimen patient . OUTLINE : Patients receive sargramostim ( GM-CSF ) intradermally ( ID ) day 1-10 begin maximum 6 month complete surgical resection . Patients receive mutant K-ras peptide vaccine ( limited specific K-ras mutation tumor ) ID day 7 . Treatment repeat every 4 week 3 course absence disease progression unacceptable toxicity . Patients follow 4 12 week . PROJECTED ACCRUAL : Approximately 30 patient accrue study within 18 month .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven stage IBIV nonsmall cell lung cancer Nonsquamous cell histology Must undergone curative surgery within past 6 month must free recurrence Tumor must demonstrate specific Kras mutation codon 12 vaccine preparation available PATIENT CHARACTERISTICS : Age : Over 17 Performance status : Karnofsky 70100 % Life expectancy : Not specify Hematopoietic : WBC least 3,000/mm^3 Platelet count least 100,000/mm^3 Hepatic : Not specify Renal : Not specify Cardiovascular : No New York Heart Association class III IV heart disease Other : Not pregnant nursing Fertile patient must use effective contraception No concurrent medical condition would preclude compliance immunologic response study treatment No serious concurrent medical condition No malignancy within past 5 year except nonmelanomatous skin cancer carcinoma situ uterine cervix PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 3 week since prior postoperative chemotherapy recover Endocrine therapy : No concurrent systemic steroid Concurrent inhale steroid allow Radiotherapy : No prior radiotherapy spleen At least 3 week since prior postoperative radiotherapy recover Surgery : See Disease Characteristics No prior splenectomy Other : No concurrent immunosuppressive drug antiinflammatory drug</criteria>
	<gender>All</gender>
	<minimum_age>17 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>stage I non-small cell lung cancer</keyword>
	<keyword>stage II non-small cell lung cancer</keyword>
	<keyword>large cell lung cancer</keyword>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
	<keyword>adenocarcinoma lung</keyword>
	<keyword>bronchoalveolar cell lung cancer</keyword>
</DOC>